NCT07204457View on ClinicalTrials.gov

Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,123

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

June 30, 2027

Conditions
Meningococcal Infections
Interventions
BIOLOGICAL

EG-MCV4

single intramuscular dose on Day 0

BIOLOGICAL

Menveo

single intramuscular dose on Day 0

Trial Locations (1)

Unknown

The Catholic University of Eunpyeong St.Mary's Hospital, Seoul

Sponsors

Lead Sponsor

EyeGene Inc.

Collaborators (1)

BMI Korea
All Listed Sponsors
collaborator

BMI Korea

INDUSTRY

lead

EyeGene Inc.

OTHER

NCT07204457 - Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old | Biotech Hunter | Biotech Hunter